Impacts of Financial Coverage on Long-Term Outcome of ICU Survivors with Lower Economic Status: Cohort Study Under National Health Insurance System in South Korea

2019 ◽  
Author(s):  
Tak Kyu Oh ◽  
In-Ae Song ◽  
Sunkyu Choi ◽  
Young-Tae Jeon
Keyword(s):  
Cohort Study ◽  
Health Insurance ◽  
South Korea ◽  
National Health Insurance ◽  
Economic Status ◽  
Health Insurance System ◽  
National Health Insurance System ◽  
Term Outcome ◽  
Long Term Outcome

scholarly journals Health Expenditure Difference according to Individual Copayment in National Health Insurance System

2021 ◽  
Vol 14 (1) ◽  
pp. 225-232
Author(s):  
Ki C. Kim ◽  
Soon C. Kwon
Keyword(s):  
Health Care ◽  
Health Insurance ◽  
South Korea ◽  
National Health Insurance ◽  
National Health ◽  
Low Ses ◽  
Health Insurance System ◽  
National Health Insurance System ◽  
Medical Expenses ◽  
The Government

Background: South Korea adopt a mandatory national health care system covering all citizens and consisting of the National Health Insurance System (NHIS) and Medical Aid Program (MAP), which cover individuals of non-low and low Socioeconomic Status (SES), respectively. Objective: We investigated and compared the medical expenses per claim in South Korea for SES individuals, to predict health care expenditure and provide fundamental data regarding care for individuals with limited finances. Methods: The inpatient data on NHIS and MAP beneficiaries were derived from the National Health Insurance Statistical Annual Report of South Korea from 2011 to 2015. Medical expenses per claim for the NHIS and MAP were investigated by gender and age, and the ratio of expenses per claim under MAP to that under NHIS was calculated. Results: The ratio from 2011 to 2015 was consistently larger than 1 and increased at an inconsistent rate with each consecutive age group until 30-39 years, and decreased thereafter (Males: 1.09-3.47, Females: 1.07-1.95). Conclusion: The results of this study indicated that higher medical expenditures and longer durations of claim in the low SES group may become obstacles to developing a sustainable health care system. The government should induce social activities of working-age low-SES people to reduce the burden on the government and help them lead a healthy life.

Incidence of exudative age-related macular degeneration and treatment load under the Korean national health insurance system in 2010–2015

2018 ◽  
Vol 103 (10) ◽  
pp. 1361-1366 ◽  
Author(s):  
Tyler Hyungtaek Rim ◽  
Tae Keun Yoo ◽  
Seo Hee Kim ◽  
Dong Wook Kim ◽  
Sung Soo Kim
Keyword(s):  
Health Insurance ◽  
South Korea ◽  
Macular Degeneration ◽  
National Health Insurance ◽  
Age Related Macular Degeneration ◽  
Newly Diagnosed ◽  
Health Insurance System ◽  
National Health Insurance System ◽  
Exudative Amd ◽  
Age Related

Background/AimThe aim of this study was to estimate the nationwide incidence of clinically diagnosed exudative age-related macular degeneration (AMD) and associated use of ranibizumab and aflibercept in South Korea.MethodsIn this retrospective, population-based cohort study, claims data for 2010–2015 were analysed in a randomly selected sample of 519 661 adults aged ≥40 years. The incidence per 10 000 person-years was estimated, along with the 95% CI. Incident exudative AMD was defined based on the registration code for rare intractable diseases. Use of ranibizumab and aflibercept and the incidence of exudative AMD were recorded.ResultsNine hundred and twelve patients were newly diagnosed with exudative AMD in 2010–2015. The 6-year incidence in the general population aged ≥40 years was 2.9 (95% CI 2.8 to 3.0) per 10 000 person-years. The incidence was highest in individuals aged 75–79 years (12.0, 95% CI 10.3 to 13.8). The incidence was higher in men than in women in all age groups. Six hundred and twenty-five (69%) of the 912 newly diagnosed patients started ranibizumab or aflibercept as a first-line treatment. The average number of injections administered was 6.1 (SD 3.9; minimum of 1 injection and maximum government-supported limit of 14) during 2010–2015; the number increased with increasing government funding support (from 5 to 10 and from 10 to 14 in 2013 and 2014, respectively).ConclusionsThis study describes the incidence of exudative AMD in South Korea and its treatment under the national health insurance system in this country. Its findings could be used for reference purposes and be useful when planning treatment for exudative AMD.

First-line treatment of advanced colorectal cancer with bevacizumab in France: The ThInDiT observational cohort study.

2012 ◽  
Vol 30 (4_suppl) ◽  
pp. 655-655
Author(s):  
Solene Doat ◽  
Solene Samson ◽  
Philippe Ricordeau ◽  
Didier Guillemot ◽  
Emmanuel Mitry
Keyword(s):  
Colorectal Cancer ◽  
Cohort Study ◽  
Health Insurance ◽  
Metastatic Colorectal Cancer ◽  
National Health Insurance ◽  
Observational Cohort Study ◽  
Line Treatment ◽  
Health Insurance System ◽  
National Health Insurance System ◽  
Observational Cohort

655 Background: ThInDiT (Therapeutic Innovations in Digestive Tumors) is an ambispective observational cohort study based on the database of the French national health insurance system. Using this database, we analysed the use of bevacizumab in the front-line treatment of metastatic colorectal cancer. Methods: Patients and treatment characteristics were collected for 4 273 incident cases of colorectal cancer with synchronous metastases diagnosed between April 1st and September 30th 2009. A logistic regression was used to identify factors predictive of non-prescription of bevacizumab among patients receiving chemotherapy within the first three months. Results: 2 757 (64.5%) received chemotherapy, in combination with bevacizumab in 827 patients (30% of the treated patients). Median age was 64 years in the bevacizumab group against 70 years in the no bevacizumab group (p<0.0001). Major factors significantly associated with the non-prescription of bevacizumab in multivariate analysis were: age ≥ 75 years (OR= 2.47, IC95% 1.9-3.1), unresected primary tumour (OR=1.44, IC95% 1.2-1.8), rectal site (OR= 1.37, IC95% 1.1-1.8), peritoneal carcinosis (OR=1.37, IC95% 1.1-1.7), radiotherapy within the last month (OR=3.59, IC95% 2.1-6.1), arterial (OR= 1.72, IC95% 1.1-2.6) or venous (OR=2.04, IC95% 1.3-3.1) thromboembolic event within 6 months, arterial hypertension (OR=1.37, IC95% 1.1-1.7), wound (OR=3.35, IC95% 1.3-8.7), chronic bronchopneumopathy (OR=1.66, IC95%: 1.0-2.7), nephropathy (OR=2.69, IC95% 1.5-4.7). Brain metastasis and colonic endoprothesis were not associated. 1-year overall survival rate was 81% in the bevacizumab group and 76% in the no bevacizumab group. Conclusions: Based on the database of the national health insurance system, this analysis reports data on the use of chemotherapy in combination with bevacizumab in the French population, reflecting the real life practice among non-selected patients. About 2/3 of the patients with synchronous metastatic colorectal cancer are treated with chemotherapy, in combination with bevacizumab in 30% of the cases. Patients receiving bevacizumab are younger with less comorbidities.

The long‐term outcome of MOGAD: An observational national cohort study of 61 patients

2021 ◽  
Vol 28 (5) ◽  
pp. 1659-1664
Author(s):  
Romain Deschamps ◽  
Julie Pique ◽  
Xavier Ayrignac ◽  
Nicolas Collongues ◽  
Bertrand Audoin ◽  
...  
Keyword(s):  
Cohort Study ◽  
Term Outcome ◽  
Long Term Outcome ◽  
National Cohort
Sign in / Sign up

Export Citation Format

Share Document